Top 3 Picks
2026 Outlook
Through 2026, premiumization, digital channels, and product innovation are expected to drive moderate sector growth, benefiting established players such as Kenvue ($30.4B) while pressuring smaller caps like Waldencast ($0.2B) on volatility. Emphasis on cost efficiency and sustainability will likely favor high-scoring firms navigating competitive pressures.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
Olaplex Holdings, Inc. Common Stock
|
59.9 | $2.07 | $867M |
|
2
|
Interparfums, Inc. Common Stock
|
57.6 | $116.69 | $3.0B |
|
3
|
Edgewell Personal Care Company
|
55.2 | $28.87 | $970M |
|
4
|
Waldencast plc Class A Ordinary Share
|
54.9 | $1.37 | $239M |
|
5
|
United-Guardian, Inc.
|
53.9 | $7.14 | $35M |
|
6
|
Colgate-Palmolive Company
|
53.1 | $88.77 | $63.9B |
|
7
|
Kenvue Inc.
|
50.8 | $18.74 | $30.4B |
|
8
|
Safety Shot, Inc. Common Stock
|
50.8 | $9.84 | $61M |
|
9
|
The Estee Lauder Companies Inc. Class A
|
48.8 | $103.86 | $31.1B |
|
10
|
cbdMD, Inc. Common Stock
|
48.6 | $0.48 | $10M |
|
11
|
COTY INC
|
45.3 | $2.93 | $3.5B |
|
12
|
Solesence, Inc. Common Stock
|
39.3 | $0.85 | $228M |
|
13
|
e.l.f. Beauty, Inc.
|
37.5 | $109.67 | $7.7B |
|
14
|
AXIL Brands, Inc.
|
33.8 | $6.24 | $40M |
In-Depth Analysis: Top Cosmetics Stocks
OLPX
Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, …
Olaplex Holdings Inc matters in the Cosmetics sector as a technology-driven company delivering science-backed hair health solutions developed through direct collaboration with professional hairstylists and consumers.
Olaplex reports a -3.5% profit margin and -1.7% ROE, reflecting current net losses and weak returns on equity, while its 2.5% revenue growth indicates limited top-line momentum.
Olaplex's 59.9/100 Tradestie Score and stylist-community model support potential share gains in haircare. Its science-enabled product pipeline could convert the existing 2.5% revenue growth into margin recovery by 2026. Investors may view the current -3.5% profit margin as a trough valuation entry point ahead of sector expansion.
IPAR
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and …
Interparfums Inc. matters in the Cosmetics sector as a key player in prestige fragrances, licensing and distributing products under brands including Coach, Jimmy Choo, Montblanc, and Moncler that target premium consumer demand in personal care.
The company shows solid financial health with an 11.2% profit margin and 19.1% ROE, reflecting efficient equity utilization, though revenue growth of only 2.1% signals limited top-line momentum at a P/E of 22.3.
Investors should consider IPAR for 2026 given its 19.1% ROE and 11.2% margins that support sustained returns, paired with a diversified luxury brand portfolio that could accelerate growth beyond the current 2.1% revenue pace. The 22.3 P/E offers reasonable entry valuation relative to sector peers, and the 57.6/100 Tradestie Score points to moderate upside potential from fragrance demand recovery.
EPC
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
Edgewell Personal Care maintains relevance in the cosmetics sector through its Sun and Skin Care segment, anchored by brands such as Banana Boat and Hawaiian Tropic, alongside Wet Shave offerings like Schick that support grooming market share.
With a profit margin of -4.2% and ROE of -1.3% against 1.7% revenue growth, Edgewell demonstrates ongoing losses and weak capital efficiency, reflecting pressure from segment costs in feminine care and wet shave operations.
A Tradestie Score of 55.2 positions Edgewell for potential 2026 recovery as its diversified personal care portfolio captures growth in sun care demand, enabling margin expansion from 1.7% revenue trends through brand optimization in Schick and Banana Boat. Cost controls in Wet Shave and Feminine Care could drive ROE improvement from the current -1.3% base, supporting earnings rebound. Investors may target the stock for undervalued exposure to steady personal care volumes amid sector consolidation.
WALD
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, …
Waldencast PLC operates in the cosmetics sector as a beauty and wellness platform with two segments, Obagi Skincare and Milk Makeup, where Obagi Medical accounts for the majority of revenue through development and marketing of skincare products.
Waldencast reports a profit margin of -84.5% and ROE of -40.3%, paired with revenue growth of -1.7%, reflecting ongoing losses and negative returns on equity that signal strained financial health.
The Tradestie Score of 54.9/100 positions Waldencast for potential stabilization in 2026 if Obagi's skincare revenue base expands amid cosmetics sector demand. Milk Makeup could contribute incremental growth to offset the -1.7% revenue trend, supporting a recovery in margins from current -84.5% levels. Investors may view the dual-segment platform as a leveraged play on wellness trends with scope for ROE improvement beyond -40.3%.
UG
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in …
United-Guardian supplies specialized cosmetic ingredients including Lubrajel Fluid and Klensoft to personal care manufacturers, serving as a niche player in the Cosmetics sector alongside its pharmaceutical and medical lubricant lines distributed through full-line drug channels.
UG posts a 22.0% profit margin and 21.3% ROE, reflecting efficient operations and strong returns on equity, while 9.5% revenue growth and a 13.1 P/E ratio indicate healthy financial positioning with reasonable valuation.
At a P/E of 13.1, UG offers an attractive entry point for 2026 relative to its 22.0% margins and 21.3% ROE, supporting potential multiple expansion if cosmetic ingredient demand accelerates. The 9.5% revenue growth trajectory positions the company to capture share in specialty formulations, with the 53.9/100 Tradestie Score leaving room for operational improvements to unlock further upside.
CL
Since its founding in 1806, Colgate-Palmolive has grown into a leading player in the household and personal care industry. In addition to its namesake oral care line (which accounts for north of 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries. International sales account for about …
Colgate-Palmolive matters in the Cosmetics sector as a leading personal care player with its oral care line driving over 40% of sales alongside shampoos, shower gels, and deodorants, sustaining relevance since its 1806 founding.
The company posts a 9.7% profit margin and 4.9% revenue growth alongside an exceptional 267.4% ROE, reflecting efficient operations and strong financial health despite a 35.5 P/E ratio.
CL offers investors exposure to steady 4.9% top-line growth and sector-leading capital efficiency via its 267.4% ROE, which supports sustained cash returns in personal care categories. Its established brands position it for incremental market share gains through 2026 as consumer spending on household and hygiene products remains resilient. At a Tradestie Score of 53.1, the stock trades at a P/E of 35.5 that appears justified by these fundamentals for long-term holding.
KVUE
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral …
Kenvue matters in the Cosmetics sector through its Neutrogena and Aveeno skincare brands, which form a key part of its $15B+ consumer health portfolio and drive exposure to personal care amid the J&J spin-off.
Kenvue shows steady financial health with a 10.8% profit margin and 15.6% ROE, backed by 3.0% revenue growth and a 22.3 P/E ratio that reflects balanced earnings valuation for its scale.
In 2026, KVUE offers a buy case via its dominant position in stable consumer health including cosmetics-adjacent lines, potential post-spin-off efficiency gains, and a 15.6% ROE paired with a 22.3 P/E supporting upside in defensive growth.
SHOT
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
Safety Shot, Inc. introduces a patented functional beverage into the Cosmetics sector by aligning alcohol-reduction wellness claims with emerging beauty-from-within trends, potentially expanding market overlap between beverage and personal care wellness products.
Limited financial data available for Safety Shot, Inc. yields a Tradestie Score of 50.8/100, reflecting moderate financial health with insufficient visibility into revenue generation or margin expansion to assess sustained profitability.
The 2026 launch of Safety Shot's alcohol-reducing beverage could drive revenue growth in wellness channels that intersect Cosmetics distribution. A Tradestie Score near 51/100 combined with patented IP positions the stock for upside if commercialization scales beyond current limited data. Investors may consider entry ahead of potential sector crossover adoption in 2026.
EL
Estée Lauder is a leader in the global prestige beauty market, participating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and others (5%), with top-selling brands such as Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 31% of …
Estée Lauder leads the global prestige beauty market, holding dominant positions across skin care (49% of fiscal 2025 sales), makeup (29%), and fragrance (17%) through brands including Estée Lauder, Clinique, M.A.C, La Mer, and Jo Malone London.
Estée Lauder reports a profit margin of 1.2% and ROE of 4.8%, reflecting constrained profitability and returns despite 6.3% revenue growth, while its P/E ratio of 201.7 indicates stretched valuation relative to current earnings.
Investors should consider EL in 2026 given its scale in prestige beauty and 6.3% revenue growth trajectory, which position the company for margin recovery above the current 1.2% level as consumer demand rebounds. Portfolio diversification across skin care, makeup, and fragrance supports market share gains in a growing sector. Compression of the elevated 201.7 P/E multiple could follow earnings improvement, delivering upside from the 48.8/100 Tradestie Score baseline.
YCBD
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and …
cbdMD, Inc. matters in the Cosmetics sector through its cbdMD brand CBD topicals and oils, which target the hemp-infused personal care niche alongside ATRx Labs functional mushrooms, supported by 20.6% revenue growth.
The company shows weak financial health with a -13.8% profit margin and -40.3% ROE, reflecting persistent losses despite 20.6% revenue growth and a low P/E of 2.1 that signals potential undervaluation.
Investors should consider YCBD in 2026 given its 2.1 P/E ratio paired with 20.6% revenue growth, which could drive re-rating if margins improve from current levels. Expansion of CBD topicals and ATRx Labs products into cosmetics channels offers scalable upside. A Tradestie Score of 48.6/100 leaves room for outperformance as operational leverage materializes.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.